Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 16,975

Document Document Title
WO/2012/004966A1
Disclosed is a drug effective in the treatment of fibromyalgia. Basically, the disclosed therapeutic agent was created on the basis of experiments showing improvement in symptoms when etanercept was administered to patients suffering fro...  
WO/2012/005568A1
The invention relates to the use of an anabolic amino acid derivative stimulus acting in combination with vitamin D for the manufacture of a medicament or nutritional composition for the prevention and/or treatment of a loss of any one o...  
WO/2012/005227A1
As a pharmaceutical product useful for patients with urine evacuation disorders for whom conventional drugs are ineffective, a drug is disclosed having inhibitory activity on ENPP2, which is a target different from that of already existi...  
WO/2012/002773A3
A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an ac...  
WO/2012/002773A2
A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an ac...  
WO/2012/001121A1
The present invention relates to a composition comprising a calpain-3 inhibitor for treating cardiomyopathies and muscular dystrophies, in particular tibial muscular dystrophy (TMD).  
WO/2012/001941A1
Disclosed is a prophylactic or ameliorating agent for a genetic disease which is induced by the mutation of an exon in a gene and in which an exon that contains the mutation is skipped so as to produce a functional truncated protein. Spe...  
WO/2011/162320A1
Disclosed is a medicament characterized by the combination of: epigallocatechin gallate, methylated epigallocatechin gallate, or a pharmacologically permitted salt thereof; and a phosphodiesterase inhibitor.  
WO/2011/160826A1
A method for treating a disease or condition caused by or associated with hyperactivity of muscles or exocrine glands in a patient, the method comprising administering a composition comprising an effective amount of Clostridium botulinum...  
WO/2011/161427A3
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α2-glycoproteins or a functional fragment...  
WO/2011/157059A1
Isoacteoside or a pharmaceutically acceptable saltthereof which is used as an inhibitor of production, accumulation or aggregation of amyloid βpeptide has effect on preventing or treating diseases or symptoms associated with amyloid βp...  
WO/2011/152618A9
The present invention relates to a method for purifying non-diffusive botulinum toxin causing local muscle paralysis, and non-diffusive botulinum toxin purified thereby, and more specifically, to a method for purifying non-diffusive botu...  
WO/2011/153277A2
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, re...  
WO/2011/151632A1
The present invention relates to the field of nutritional support for individuals and reducing the effects of muscle conditions caused by high levels of physical activity. In particular, the invention provides dietary formulations, compo...  
WO/2011/152618A2
The present invention relates to a method for purifying non-diffusive botulinum toxin causing local muscle paralysis, and non-diffusive botulinum toxin purified thereby, and more specifically, to a method for purifying non-diffusive botu...  
WO/2011/150457A3
The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGD...  
WO/2011/152618A4
The present invention relates to a method for purifying non-diffusive botulinum toxin causing local muscle paralysis, and non-diffusive botulinum toxin purified thereby, and more specifically, to a method for purifying non-diffusive botu...  
WO/2011/152618A3
The present invention relates to a method for purifying non-diffusive botulinum toxin causing local muscle paralysis, and non-diffusive botulinum toxin purified thereby, and more specifically, to a method for purifying non-diffusive botu...  
WO/2011/152524A1
The disclosed cell growth-promoting agent contains as active ingredient, an artificially synthesized peptide comprising (A) an amino acid sequence that configures a membrane-penetrating peptide and (B) an amino acid sequence that configu...  
WO/2011/151432A1
The present invention relates to humanised antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding protein...  
WO/2011/153277A3
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, re...  
WO/2011/147967A1
The present invention relates to a therapeutic substance and/or medicament and methods relating to the use of said substance and/or medicament for skeletal muscle regeneration using mesenchymal stem cells (MSCs) which can be applied dire...  
WO/2011/150008A1
The present invention provides isolated human or humanized antibodies or antigen- binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragme...  
WO/2011/147086A1
Microvesicles containing small interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing small interfering RNAs are also provided. Microvesicles cont...  
WO/2011/145909A3
The present invention relates to the novel use of panduratin derivatives or an extract of Boesenbergia pandurata for promoting muscle mass growth, fighting fatigue, and enhancing exercise performance capability. More particularly, the pr...  
WO/2011/143526A2
A method of treating peripheral neuropathic pain in humans resulting from a peripheral nerve injury and for treating muscle spasm in humans resulting from a peripheral nerve injury comprises applying a therapeutically effective amount of...  
WO/2011/142316A1
Disclosed is a nitrogen-containing heterocyclic compound represented by formula (I) or a pharmacologically acceptable salt thereof, which has kynurenine production inhibitory activity. (In formula (I), R6 and R7 may be the same or differ...  
WO/2011/143187A3
The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As de...  
WO/2011/143152A3
Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in...  
WO/2011/141891A1
The present invention relates to cycloundecadepsipeptide compound analogues presenting mitochondrial permeability transition pore (MPTP) inhibitory activity and reduced cytotoxicity. The present invention further relates to a pharmaceuti...  
WO/2011/143187A2
The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As de...  
WO/2011/143008A1
The invention provides compositions and associated methods for the antisense treatment of genetic disorders, infections and various other medical conditions. In particular, embodiments of the present invention are directed to pharmaceuti...  
WO/2011/143526A9  
WO/2011/143152A2
Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in...  
WO/2011/135969A1
Disclosed is a method for efficiently and conveniently producing iPS cells. Pluripotent stem cells are obtained by culturing bone marrow in the presence of granulocyte-monocyte colony-stimulating factor, and then genetically transforming...  
WO/2011/130908A1
The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.  
WO/2011/133985A1
A method for forming neuromuscular junctions includes forming functional neuromuscular junctions between motoneurons and muscle cells by co-culturing one or more human motoneurons and one or more human muscle cells in a substantially ser...  
WO/2011/130515A1
Aryl substituted thiazol-2-yl-piperidines and related compounds useful as modulators of survival motor neuron (SMN) protein production are provided herein. Without being bound to any particular theory it is believed the aryl substituted ...  
WO/2011/125836A1
Disclosed is a therapeutic agent or prophylactic agent that has analgesic effects on both nociceptive pain and neuropathic pain and is effective in the treatment of fibromyalgia. Specifically disclosed is a therapeutic agent or prophylac...  
WO/2011/121109A1
The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator .  
WO/2011/123456A1
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injec...  
WO/2011/117448A1
The invention relates to compounds for use in the treatment of diseases based on the expression of toxic transcripts. The invention relates to peptide molecules, specifically hexapeptides, for the prevention and/or treatment of diseases ...  
WO/2011/115184A1
Disclosed is an inhibitor of in vivo proteolysis, which contains, as an active ingredient, a fatty acid compound that contains one acyl group having 6-12 carbon atoms. The inhibitor of in vivo proteolysis preferably contains, as an activ...  
WO/2011/115183A1
Disclosed is a monocyclic pyrimidine derivative. To be more specific, the pyrimidine derivative is effective in the prophylaxis and/or treatment of disorders associated with signal transmission mediated by Toll-like receptors (TLR).  
WO/2011/111714A1
Disclosed are: a compound which has excellent metabolic stability and selectively binds to EP4 receptor; and a pharmaceutical product which contains the compound. Specifically disclosed is a compound represented by formula (1) (wherein R...  
WO/2011/111698A1
Disclosed is a monoclonal antibody against a biomarker capable of highly specific and effective use in the detection and diagnosis of various pathologies associated with various types of cancer nests and necrotic focuses. The monoclonal ...  
WO/2011/111694A1
Disclosed is a monoclonal antibody against a biomarker capable of highly specific and effective use in the detection and diagnosis of various pathologies associated with various types of cancer nests and necrotic focuses. The monoclonal ...  
WO/2011/108009A3
The present invention relates to a process for the preparation of substantially pure fampridine compound of structural formula (I), (II), (III) comprising nitrifying pyridine-N-oxide hydrochloride with suitable nitrating agent; reducing ...  
WO/2011/108692A1
Disclosed is an agent for preventing muscular atrophy, which has an excellent preventive effect on muscular atrophy and comprises a whey protein hydrolysate. Specifically disclosed is an agent for preventing muscular atrophy, which compr...  
WO/2011/109324A1
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...  

Matches 351 - 400 out of 16,975